Intracerebral delivery of antiseizure medications by microinvasive neural implants
Brain · 2024
DOI: 10.1093/brain/awae282 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain, 2024. Verfasst von Hannah D Jackson und 7 weiteren Autor:innen. Beteiligte Einrichtung: Harvard-MIT Program in Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA. Hauptthemen laut MEDLINE: Anticonvulsants, Phenobarbital, Epilepsy, Temporal Lobe, Valproic Acid. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Deshpande Center for Technological Innovation at MIT, NIH HHS, University of Utah.
Abstract (Originalsprache)
Focal epilepsy is a difficult disease to treat as two-thirds of patients will not respond to oral anti-seizure medications (ASMs) or have severe off-target effects that lead to drug discontinuation. Current non-pharmaceutical treatment methods (resection or ablation) are underutilized due to the associated morbidities, invasive nature and inaccessibility of seizure foci. Less invasive non-ablative modalities may potentially offer an alternative. Targeting the seizure focus in this way may avoid unassociated critical brain structures to preserve function and alleviate seizure burden. Here we report use of an implantable, miniaturized neural drug delivery system [microinvasive neural implant infusion platform (MINI)] to administer ASMs directly to the seizure focus in a mouse model of temporal lobe epilepsy. We examined the effect local delivery of phenobarbital and valproate had on focal seizures, as well as adverse effects, and compared this to systemic delivery. We show that local delivery of phenobarbital and valproate using our chronic implants significantly reduced focal seizures at all doses given. Furthermore, we show that local delivery of these compounds resulted in no adverse effects to motor function, whereas systemic delivery resulted in significant motor impairment. The results of this study demonstrate the potential of ASM micro dosing to the epileptic focus as a treatment option for people with drug resistant epilepsy. This technology could also be applied to a variety of disease states, enabling a deeper understanding of focal drug delivery in the treatment of neurological disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Harvard-MIT Program in Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
- Anticonvulsant Drug Development Program, University of Utah, Salt Lake City, UT 84112, USA.
- Department of Biomedical Engineering, University of Utah, Salt Lake City, UT 84112, USA.
- Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, UT 84112, USA.
- Department of Materials Science and Engineering, Koch Institute of Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
ORCID-Profile: Hannah D Jackson, Karen S Wilcox
Förderung
- Deshpande Center for Technological Innovation at MIT
- NIH HHS
- University of Utah
- National Institutes of Health
Zitieren
APA
Jackson, H. D., Cotler, M. J., Saunders, G. W., Cornelssen, C. A., West, P. J., Metcalf, C. S., Wilcox, K. S., & Cima, M. J. (2024). Intracerebral delivery of antiseizure medications by microinvasive neural implants. Brain. https://doi.org/10.1093/brain/awae282
Vancouver
Jackson HD, Cotler MJ, Saunders GW, Cornelssen CA, West PJ, Metcalf CS, et al. Intracerebral delivery of antiseizure medications by microinvasive neural implants. Brain. 2024. doi:10.1093/brain/awae282
BibTeX
@article{Jackson2024,
author = {Jackson, Hannah D and Cotler, Max J and Saunders, Gerald W and Cornelssen, Carena A and West, Peter J and Metcalf, Cameron S and Wilcox, Karen S and Cima, Michael J},
title = {Intracerebral delivery of antiseizure medications by microinvasive neural implants},
journal = {Brain},
year = {2024},
doi = {10.1093/brain/awae282}
}
EUVIMED